Transmembrane proteins (TPs) are crucial components of cell membranes, involved in processes like substance transport, signal transduction, and cell recognition. Their dysfunction is linked to various diseases, making them key drug targets. Over 60% of known drug targets are TPs, and nearly 90% of antibody drug targets are TPs. However, drug development targeting these proteins is challenging due to their hydrophobic nature, which makes maintaining their native structure difficult in vitro, along with low expression levels of full-length TPs.

To advance drug development, DIMA BIOTECH has developed several solutions for TPs preparation. Using the HEK293 cell expression system, they express recombinant membrane proteins close to their natural conformation. For single-pass TPs, an extracellular domain (ECD) fusion protein system is used, while for full-length TPs like GPCRs and Claudins, they utilize seven major expression platforms, including both purified and non-purified options. The purified platforms include: Synthetic Nanodisc, MSP Nanodisc, PeptiNanodisc, and Detergent systems, while the non-purified platforms include: MNP, VLP, and Exosome systems.